Abstract
BackgroundAlpha-synuclein (asyn) has been shown to play an important role in the neuropathology of Parkinson’s disease (PD). In the diseased brain, classic intraneuronal inclusions called Lewy bodies contain abnormal formations of asyn protein which is mostly phosphorylated at serine 129 (pS129 asyn). This suggests that post-translational modifications may play a role in the pathogenic process. To date, several uniplex assays have been developed in order to quantify asyn not only in the brain but also in cerebrospinal fluid and blood samples in order to correlate asyn levels to disease severity and progression. Notably, only four assays have been established to measure pS129 asyn specifically and none provide simultaneous readout of the total and pS129 species. Therefore, we developed a sensitive high-throughput duplex assay quantifying total and pS129 human asyn (h-asyn) in the same well hence improving accuracy as well as saving time, consumables and samples.ResultsUsing our newly established duplex assay we measured total and pS129 h-asyn in vitro showing that polo-like kinase 2 (PLK2) can phosphorylate asyn up to 41 % in HEK293 cells and in vivo the same kinase phosphorylated h-asyn up to 17 % in rat ventral midbrain neurons. Interestingly, no increase in phosphorylation was observed when PLK2 and h-asyn were co-expressed in rat striatal neurons. Furthermore, using this assay we investigated h-asyn levels in brain tissue samples from patients with PD as well as PD dementia and found significant differences in pS129 h-asyn levels not only between disease tissue and healthy control samples but also between the two distinct disease states especially in hippocampal tissue samples.ConclusionsThese results demonstrate that our duplex assay for simultaneous quantification is a useful tool to study h-asyn phosphorylation events in biospecimens and will be helpful in studies investigating the precise causative link between post-translational modification of h-asyn and PD pathology.Electronic supplementary materialThe online version of this article (doi:10.1186/s13024-016-0125-0) contains supplementary material, which is available to authorized users.
Highlights
Alpha-synuclein has been shown to play an important role in the neuropathology of Parkinson’s disease (PD)
Specificity of antibodies for establishing human alpha-synuclein AlphaLISA assays We began our work towards developing an asyn selective assay by examining the specificity of various commercially available or custom generated antibodies to asyn (Table 1)
Whereas the C-20 antibody (Santa Cruz, USA) recognized both the rat and human asyn protein at the expected molecular weight of 17 kDa, LB509 (Covance, USA), syn204 (Cell Signaling, USA), syn211 (Abcam, UK) and 4B12 (Covance, USA) antibodies appeared to be specific to the human variant
Summary
Alpha-synuclein (asyn) has been shown to play an important role in the neuropathology of Parkinson’s disease (PD). Classic intraneuronal inclusions called Lewy bodies contain abnormal formations of asyn protein which is mostly phosphorylated at serine 129 (pS129 asyn). This suggests that post-translational modifications may play a role in the pathogenic process. None of the above methods implemented a duplex assay platform to measure the total asyn and pS129 asyn in a single well This is important to save samples, consumables and time and to measure asyn phosphorylation ratios more accurately especially when pS129 asyn levels are very low
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.